-+ 0.00%
-+ 0.00%
-+ 0.00%

JP Morgan Maintains Overweight on Amneal Pharmaceuticals, Raises Price Target to $25

Benzinga·11/04/2026 19:27:56
Listen to the news
JP Morgan analyst Chris Schott maintains Amneal Pharmaceuticals (NASDAQ:AMRX) with a Overweight and raises the price target from $24 to $25.